Epidemiology and renal injury following 2-methyl-4-chlorophenoxyacetic acid (MCPA) poisoning.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 12 2022
19 12 2022
Historique:
received:
17
01
2022
accepted:
28
11
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
22
12
2022
Statut:
epublish
Résumé
2-Methyl-4-chlorophenoxyacetic acid (MCPA) is a widely used chlorophenoxy herbicide. MCPA poisoning causes mitochondrial dysfunction, which can lead to kidney injury and death. The objective of this study is to describe the epidemiology, case fatality and extent of renal injury in a large cohort of MCPA self-poisonings. The study consists of two parts: (1) A report of epidemiological data and clinical outcomes in MCPA poisoned patients in Sri Lanka between 2002 and 2019; (2) Evaluation of acute kidney injury (AKI) using renal biomarkers in a subset from this cohort. Serum creatinine (sCr) and biomarkers were measured soon after hospitalization (2 [IQR 1-3] h) and at different time intervals. We measured serum biomarkers: sCr, cystatin C (sCysC), creatine kinase (CK), and urinary biomarkers: creatinine, kidney injury molecule-1 (KIM-1), clusterin, albumin, beta-2-microglobulin (β2M), cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), trefoil factor 3 (TFF3) and cytochrome C (CytoC). Kidney Disease Improving Global Outcomes (KDIGO) criteria was used to define acute kidney injury (AKI). There were 1653 patients; 65% were male. The median time from ingestion to examination was 3:54 (IQR 2:19-6:57) h. The overall case-fatality rate was 5.3%. Patients who died were older (42 [IQR 33.5-54] vs 27 [IQR 20-37] for survivors). The median estimated amount of MCPA ingested by patients who died was also greater (88 [IQR 34-200] vs. 30 [IQR 15-63] ml in survivors). Moderate to severe AKI (AKI2/3) was uncommon (6/59 patients in the biomarker study had KDIGO stage 2 or 3). Most patients in AKI2/3 group with increased sCr were older (median age 35 years [IQR 27-41]) compared to No AKI (23 years (19-29) years) or AKI1 (26 years (21-40) years) group who had no or mild increase in sCr. These patients had no pre-existing kidney diseases. In these patients, serum creatinine (maximum medium concentration; 1.12 [IQR 0.93-1.67] mg/dl) and CK (maximum medium concentration; 284 [IQR 94-428] U/l) were increased but sCysC (maximum medium concentration; 0.79 [IQR 0.68-0.81] mg/l) remained in the normal range within 72 h. All urinary biomarkers performed poorly in diagnosing AKI (area under the receiver operating characteristic curve < 0.68). The higher numbers of men with MCPA poisoning likely reflects greater occupational access to pesticides. Fatal outcome and higher ingested dose were more common in the elderly. Significant AKI with tubular injury biomarkers was uncommon. Most people with raised sCr were older and appeared to have no pre-existing kidney disease.
Identifiants
pubmed: 36535986
doi: 10.1038/s41598-022-25313-z
pii: 10.1038/s41598-022-25313-z
pmc: PMC9763389
doi:
Substances chimiques
2-Methyl-4-chlorophenoxyacetic Acid
D888C394VO
Biomarkers
0
Creatinine
AYI8EX34EU
Cystatin C
0
Lipocalin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21940Informations de copyright
© 2022. The Author(s).
Références
Environ Toxicol Pharmacol. 2020 Nov;80:103510
pubmed: 33031936
J Res Med Sci. 2018 Sep 24;23:82
pubmed: 30294350
Clin Toxicol (Phila). 2019 Nov;57(11):1080-1086
pubmed: 30888889
Clin Toxicol (Phila). 2017 Nov;55(9):970-976
pubmed: 28535124
Ann Emerg Med. 2005 Sep;46(3):275-84
pubmed: 16126140
Clin Toxicol (Phila). 2018 Sep;56(9):861-863
pubmed: 29382245
Clin Toxicol (Phila). 2009 Sep;47(8):836-7
pubmed: 19725771
Stroke. 2011 Jul;42(7):1826-33
pubmed: 21546482
Toxicol Lett. 2015 Sep 2;237(2):140-50
pubmed: 26071311
Toxicol Lett. 2011 Mar 25;201(3):270-6
pubmed: 21256202
J Toxicol Clin Toxicol. 2000;38(2):111-22
pubmed: 10778907
J Res Pharm Pract. 2018 Oct-Dec;7(4):178-181
pubmed: 30622984
Lancet Glob Health. 2021 Jun;9(6):e854-e862
pubmed: 33901424
Toxicol Lett. 2018 Dec 15;299:182-190
pubmed: 30300734
Indian J Nephrol. 2013 May;23(3):180-3
pubmed: 23814415
Sci Rep. 2017 Jan 23;7:41012
pubmed: 28112204
Biochem Res Int. 2012;2012:951539
pubmed: 22482055
Annu Rev Pharmacol Toxicol. 2008;48:463-93
pubmed: 17937594
Br J Psychiatry. 2005 Dec;187:583-4
pubmed: 16319413
Nat Biotechnol. 2010 May;28(5):470-7
pubmed: 20458317
Front Med (Lausanne). 2017 Jun 15;4:73
pubmed: 28664159
Crit Care. 2007;11(2):R31
pubmed: 17331245